Charlotte Heart Group Research Center

Port Charlotte, Florida 33952

0 studies enrolling now · 14 studies all time

What they study most

Acute Coronary Syndrome, Atrial Fibrillation, Cardiovascular Disease, Chronic Heart Failure, Chronic Heart Failure With Preserved Systolic Function, Chronic Heart Failure With Reduced Systolic Function, Congestive Heart Failure, Coronary Artery Disease, Coronary Heart Disease (CHD), Heart Failure, High Cardiovascular Risk, Myocardial Infarction

Studies at this site

• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke — Completed
• EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction) — Completed
• Dapagliflozin in PRESERVED Ejection Fraction Heart Failure — Completed
• Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure — Completed
• INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure — Completed
• A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure — Stopped early
• Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg — Completed
• EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan — Completed
• Study to Evaluate the Effects of Oral Administration of Lixivaptan in Patients With Congestive Heart Failure — Completed
• Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1) — Stopped early